Document resource
Background and Importance Non-occupational Post-Exposure Prophylaxis (nPEP) is an effective HIV (human immunodeficiency virus) prevention strategy administered after potential exposure. HIV Pre-Exposure Prophylaxis (PrEP) is also a highly effective preventive intervention designed to reduce HIV transmission in individuals with high-risk sexual behaviours.Aim and Objectives Investigated whether the introduction of PrEP (since 2021) has influenced the demand for nPEP at our centre. To characterise and evaluate both prevention strategies in terms of demographic profiles, exposure types and clinical follow-up.Material and Methods This observational, retrospective, and comparative study between nPEP usage (number of prescriptions per month) before availability of PrEP (P1=2015-2021) and after its introduction (P2=2021-2025). Comparisons between periods were conducted using a two-sample test of proportions, statistical significance set at p<0.05. Analyses were performed using RStudio for Windows (v4.4.1).Results There were 22 nPEP-prescriptions in P1 and 51 during P2. The demand for nPEP increased significantly (by 342.21%) from 0.289 prescriptions per month in P1 to 0.989 in P2, when PrEP was more available (p-value 0.002).The characteristics of all nPEP users (P1+P2) were statistically comparable to those of PrEP users (p-value <0.05). A PrEP-gap transition was identified between the two strategies.Conclusion and Relevance The increase in nPEP use may reflect heightened awareness of HIV prevention and knowledge of available interventions, as well as exposure scenarios not preventable by PrEP alone.Currently, many individuals who could benefit from PrEP remain underserved due to structural and social barriers. Strengthening care coordination and the integrating both strategies–particularly through rapid-start protocols (PEP-to-PrEP)–are essential in bridging the PrEP-gap and further reducing HIV transmission.Abstract 5PSQ-161 Table 1 Number (proportion%) nPEP-P1(n=22) nPEP-P2 (n=51) p-value nPEP P1+P2)(n=73) PrEP-users (n=47) p-value Age, years (median (IQR)*) 34(27-39) 31(27-38) 0.413 32(27-39) 35(29-43) 0.0619 Gender MenWomenTransgender-women 20(90.91%)1(4.55%)1(4.55%) 34(66.67%)14(27.45%)3(5.88%) 0.078 54(73.97%)15(20.54%)4 (5.48%) 45(95.74%)-2 (4.26%) 0.003 Men who has sex with men (MSM) 8 (36,36%) 23 (45,10%) 0.174 22(30,13%) 47(100%) 0.0005 Risky sexual intercourse Sexual assault 15(68.18%) - 39(76.47%) 11(21,57%) 0.497 54(73.97%) 11(21,57%) - - nPEP <24 h initiation 9(40.91%) 28(54.90%) 1 37(50.68%) - - Weekend exposition 8 (36.36%) 28 (54.09%) 0.2307 36 (49.32%) - - ITS* Follow-up adherence 3(13.64%) 9(40.91%) 8(15.69%) 25(49.02%) 1 11(15.07%) 34(46.58%) 29(61.70%) 35(85.71%) 0,0359 *ITS: Sexually Transmitted Infections. IQR: Interquartile RangeReferences and/or Acknowledgements SiPrEP. UNAIDS. SEIMC. SEFH.Conflict of Interest No conflict of interest